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Abstract: Purpose: The prognostic value of aberrant C-X-C chemokine receptor type 4 (CXCR4) levels in NSCLC has 
been described in empirical studies. This meta-analysis evaluates the value of CXCR4 as a prognostic marker for 
NSCLC and determines the relationship between CXCR4 and clinicopathological features of NSCLC. Methods: A 
comprehensive search of the English-language literature in PubMed, Embase, Google Scholar and Web of Science 
was performed. Articles containing sufficient published data to determine an estimate of the hazard ratio (HR) and 
a 95% confidence interval (95% CI) for over survival (OS) or disease-free survival (DFS) were selected. Of 417 poten-
tially relevant studies, 10 eligible studies (1,334 NSCLC patients) met the inclusion criteria. Results: Overall, high 
CXCR4 expression was significantly associated with a poor OS rate (HR=1.59, 95% CI=1.36-1.87, P<0.001) while 
the association with DFS was not statistically significant (HR=1.00, 95% CI=0.37-2.69, P=0.993). Stratified analysis 
by subcellular localization found that CXCR4 overexpression in the non-nucleus predicts poor OS (HR=1.65, 95% 
CI=1.40-1.95, P<0.001) and DFS (HR=3.06, 95% CI=2.15-4.37, P<0.001), but elevated CXCR4 expression in the 
nucleus was positively associated with DFS (HR=0.44, 95% CI=0.26-0.75, P=0.002). NSCLC patients with CXCR4 
expression were more likely to be diagnosed with adenocarcinoma cancer (OR=1.45, 95% CI=1.07-1.95, P=0.016), 
lymph node involvement (OR=0.69, 95% CI=0.50-0.96, P=0.027), and distant metastasis (OR=0.36, 95% CI=0.14-
0.93, P=0.035). Conclusion: Aberrant overexpression of CXCR4 is associated with worse overall survival, adenocar-
cinoma histology, distant metastasis, lymph node involvement in NSCLC. 
Keywords: NSCLC, CXCR4, prognosis, clinicopathological features, meta-analysis
Introduction
Lung cancer continues to be the leading cause 
of cancer-related death in both men and women 
throughout the world and only 15% of lung can-
cer patients survived 5 years or more [1]. It is 
known that non-small cell lung carcinoma 
(NSCLC) accounts for approximately 80% of all 
lung cancers. Identification of prognostic bio-
markers may lead to new therapies. The C-X-C 
Chemokine receptor type 4 (CXCR4) protein is 
expressed in NSCLC and may predict 
prognosis.
CXCR4 receptor is an alpha-chemokine recep-
tor specific for CXCL12 [2]. Many investigators 
have reported that the CXCR4/CXCL12 axis 
contributes to cancer progression [3]. During 
the last five years, several meta-analysis about 
prognostic value of aberrant CXCR4 levels in 
the nucleus and/or cytoplasm have been 
described in breast cancer [4], gastric cancer 
[5], esophageal cancer [6] and ovarian cancer 
[7]. To the best of our knowledge, no meta-anal-
ysis data on the correlation of CXCR4 expres-
sion with the prognosis and survival of patients 
with NSCLC have been done in the English lit-
erature. Therefore, we performed a meta-analy-
sis to evaluate the CXCR4 as a prognostic mark-
er for NSCLC and determine the relationship 
between CXCR4 and several clinicopathological 
features of NSCLC.
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Methods and materials
Search strategy
Original English articles studying the prognostic 
value of CXCR4 in NSCLC were identified with a 
comprehensive literature search in PubMed, 
Embase, Google Scholar, and Web of Science 
on September 14, 2014. Studies were identi-
fied using the following search terms: “CXCR4” 
or “C-X-C chemokine receptor type 4” AND 
“NSCLC” or “non-small lung cancer” or “non-
small cell lung cancer” or “non-small cell lung 
carcinoma” AND “prognosis” or “prognostic” or 
“outcome” or “survival”. All articles were 
reviewed for inclusion by one reviewer. Another 
independent review of all articles was conduct-
ed by a second reviewers.
Selection criteria
All articles included met the following inclusion 
criteria: a) articles detecting expression of 
CXCR4 in tumor tissues; b) articles evaluating 
the relationship between CXCR4 expression 
and parameters such as clinicopathological 
features and prognostic factors of NSCLC; c) 
articles containing sufficient published data to 
determine an estimate of the hazard ratio (HR) 
and a 95% confidence interval (95% CI) for over 
survival (OS) or disease-free survival (DFS). The 
exclusion criteria included the following: a) no 
dichotomous groups of CXCR4 expression; b) 
Letters to the editor, reviews, comments, dupli-
cated studies and articles published in books.
Data extraction
Two reviewers independently assessed the arti-
cles and resolved discrepancies via discussion 
and consensus (Table 1). Standardized abstrac-
tion sheets were used to record data from indi-
vidual studies. Data retrieved from the litera-
ture included first author, year of publication, 
country of origin, number of analyzed patients, 
NSCLC subtype, staining methods of CXCR4, 
cutoff scores, T category (tumor category: T0-2, 
T3-4), N category (lymph node status), TNM cat-
egory (I-II, III-IV), distant metastasis, ratio of 
high/low CXCR4 expression to the study out-
comes, and HR estimation. For each study, the 
HR was estimated using the method reported 
by Parmar et al. [8]. HR estimates and 95% CIs 
were either directly obtained from the original 
article or calculated using parameters such as 
statistics of observed minus expected events 
and variance provided in the papers. Otherwise, 
the number of patients at risk in each group, as 
well as the number of events and P value of the 
log-rank statistic, was retrieved to allow approx-
imate calculation of the HR estimate and its 
variance. If the study did not provide the HR but 
reported the survival curve, survival rates at 
specified time points were extracted to recon-
struct the HR estimate and its variance, with 
the assumption that the rate of patients cen-
sored was constant during the follow-up [9]. 
Survival rates on the graphical representation 
of the survival curves were read by Engauge 
Digitizer version 2.5.
Quality assessment
In this meta-analysis, quality assessment of 
the cohort studies was performed using the 
Newcastle Ottawa Scale (NOS), as recommend-
ed by the Cochrane Non-randomized Studies 
Methods Working Group [10]. The NOS con-
tains eight items under three categories: selec-
tion (four items, one star each), comparability 
(one item, up to two stars), and outcome (three 
items, one star each). Given the variability in 
the quality of cohort studies found in our initial 
literature search, we considered studies as of 
high quality if they scored six stars or more [11].
Statistical analysis
The meta-analysis was performed using STATA 
version 11 (StataCorp LP, College Station, TX, 
USA). Combined HR and 95% CI were used to 
assess the strength of association of CXCR4 
expression with OS or DFS; combined OR and 
95% CI were used to assess the strength of 
association of CXCR4 expression with clinico-
pathological features of NSCLC, P<0.05 indi-
cated statistical significance. Heterogeneity 
was assessed using I2 and Q statistics. For the 
I2 statistic, heterogeneity was interpreted as 
absent (I2<25%), moderate (I2=25%-50%), or 
extreme (I2=50%-100%) [12]. For the Q statis-
tic, P<0.10 was considered statistically signifi-
cant for heterogeneity. The pooled HR estima-
tion of each study was calculated using a ran-
dom-effects model when P<0.10 or I2≥50%; 
otherwise (P>0.10 and I2<50%), a fixed-effects 
model was used [13]. Subgroup analysis was 
conducted to explore the sources of heteroge-
neity, and differences between subgroups were 
assessed using methods described by Deeks 
et al [14]. To validate the robustness of the 
meta-analysis findings, sensitivity analysis was 
CXCR4 and cancer prognosis
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Table 1. Characteristics of eligible studies
First 
author 
(Year)
Ref. source CXCR4 assay cases
NSCLC 
subtype 
(high/
low)
T category 
(T1/2/3/4)
N 
category 
(N+/N-)
Distant 
metas- 
tasis
(M1/M0)
TNM (I/II/
III/IV)
Gender 
(high/
low)
Cut off 
(high/low)
OS DFS subcel-
lular local-
ization 
 
Progno-
sis value 
NOS 
scoreHR
(95% CI) 
HR  
(96% CI) 
Spano 
(2004)
29 France IHC 61 AC32 
(8/24)
H: (6/11/0/0) NR H: 
(4/13)
NR M: 48 
(12/36) 
Staining 50% 
(17/44)
0.83
(0.09-8.06)¶
NR nucleus positive 7
N-AC29 
(9/20)
L: 
(22/22/0/0)
L: 
(15/29)
F: 13 
(5/8)
Song 
(2008)
28 Korea IHC 323 AC145 
(23/122)
NR H: 
(29/19)
H:
 (24/24)
H: (17/9/ 
21/1)
M: 254 
(40/214) 
Scores ≥2 
(48/275)
1.351 
(1.096-1.709)
3.16 
(2.10-4.78)¶
cytoplasm 
nucleus
poor 7
N-AC178 
(25/153)
L: 
(127/148)
L: 
(94/181)
L: (128/62 
/81/4)
F: 69 
(8/61)
Suzuki 
(2008)
30 Japan IHC 90 NR NR NR NR NR NR Staining 50% 
(22/68)
2.22 
(1.13-4.37)¶
NR cytoplasm 
membrane
poor 6
Iwakiri 
(2009)
34 Japan RT-PCR 79 NR NR NR NR NR NR CXCR4>0.112 
04(40/39)
0.611
(0.226-1.654)
0.651 
(0.242-1.748)
nucleus NS 6
Wagner 
(2009)
31 USA IHC 154 AC132 
(57/75)
H: 
(40/14/0/8)
H: 
(16/46)
H: 
(4/58)
H: (40/5/ 
13/4)
M: 46 
(17/29) 
Scores ≥2 
(62/92)
NR 0.38 
(0.17-0.89)
nucleus positive 7
N-AC22 
(5/17)
L: 
(40/33/1/18)
L: 
(28/64)
L: 
(2/90)
L: (50/14/ 
26/2)
F: 108 
(45/63)
Wagner* 
(2009)
31 USA IHC 154 AC132 
(42/90)
H: 
(24/13/1/9)
H: 
(13/34)
H: 
(4/42)
H: (27/4/ 
11/5)
M: 46 
(15/31)
Scores ≥2 
(47/107)
NR 2.8 
(1.4-5.7)
cytoplasm poor 7
N-AC22 
(5/17)
L: 
(56/34/0/17)
L:
 (31/76)
L: 
(1/106)
L: (63/15/ 
28/1)
F: 108 
(32/76)
Minamiya 
(2010)
26 Japan RT-PCR 79 AC79 
(37/42)
NR H: (5/32) NR H: (32/1/ 
4/0)
M: 43 
(20/23) 
CXCR4 mRNA> 
2.4 (37/42)
0.73 
(0.17-3.10)¶
0.36 
(0.13-0.94)
nucleus positive† 6
N-AC0 L: (14/28) L: (25/6/ 
11/0)
F: 36 
(17/19)
Otsuka 
(2011)
27 Canada FIHCS 170 AC91 
(8/83)
NR NR H: 
(20/9)
NR M: 86 
(19/67)
AQUA score > 
3371 (29/141)
2.03
(1.35-3.05)¶
NR non-nucleus poor 6
N-AC79 
(21/58)
L: 
(101/40)
F: 84 
(10/74)
Wang 
(2011)
35 China IHC 208 AC90 
(56/34)
H: 
(34/42/33/8)
H: (89/28) NR H: (21/49/ 
37/0)
M: 128 
(74/54) 
Scores ≥2 
(117/91) 
2.070 
(1.365-3.140)
NR cytoplasm poor† 9
N-AC118 
(61/57)
L: 
(49/31/8/3)
L: (53/38) L: (20/42/ 
29/0)
F: 80 
(43/37)
Franco 
(2012)
33 Italy IHC 45 AC16 
(14/2)
NR H: (5/28) NR NR NR Staining 30% 
(19/26)
2.40
(0.30-18.95)¶
NR cytoplasm 
membrane
poor 6
N-AC29 
(19/10)
L: (1/11)
AlZobair 
(2013)
32 China IHC 125 AC64 
(34/30)
NR NR H: 
(26/36)
H: (3/7/ 
26/26) 
M: 87 
(42/45) 
staining 10% 
(62/63)
2.172 
(1.229-3.839)
NR cytoplasm poor 7
N-AC61 
(28/33)
L: 
(5/58)
L: (13/16/ 
29/5)
F: 38 
(20/18)
Note: ¶Extrapolated from survival curve and HR from univariate; †independent prognostic factors; *Date from the same study of the previous line; Ref., Reference number; IHC, immunohistochemistry; RT-PCR, reverse transcription-polymerase 
chain reaction; FIHCS, fluorescent immunohistochemical staining; AC, Adenocarcinoma; N-AC, Non-Adenocarcinoma; M, male; F, female; NR, Not reported; OS, over survival; DFS, disease-free survival; NS, No significance.
CXCR4 and cancer prognosis
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performed by sequentially omitting each indi-
vidual study using the “metainf” STATA com-
mand. Potential publication bias was evaluated 
using Begg’s asymmetry tests [15]. When the 
statistical significance of Egger’s test results at 
P<0.10, we also conducted a trim and fill analy-
sis [16].
Results
Search results
The study identification and selection process-
es are presented in Figure 1. Initially, 417 rele-
vant studies were identified using the search 
strategy above. After reading the titles or 
abstracts, 395 studies were excluded since 
they were duplicates, review articles, confer-
ence abstracts, animal studies or not of cohort 
design. In the remaining 21 published studies, 
11 were excluded because they were published 
in non-English languages; lack data for calcula-
tion of HR and 95% CI; or not detected in tissue 
samples. Finally, a total of 10 eligible studies 
were included in this meta-analysis [17-26].
Study characteristics
Main characteristics of the 10 studies are list-
ed in Table 1. They were published during the 
among the studies. Among all of the included 
studies, HRs and 95% CIs for OS were obtained 
directly from 4 original articles. Same number 
of articles provided HRs and 95% CIs for DFS. 
For the remaining studies, HRs and 95% CIs 
were calculated or extrapolated from Kaplan-
Meier curves. The mean value of the article 
quality was 6.7 out of 9 stars (Table 1).
Correlation of CXCR4 expression with clinico-
pathological parameters
We only chose the studies [19-24, 26] which 
CXCR4 expression examined by IHC to evaluate 
the correlation of CXCR4 expression with gen-
der, Adenocarcinoma (AC), T category, N cate-
gory, TNM stage and distant metastasis (Figure 
2). The pooled OR indicated that CXCR4 expres-
sion did not have significant correlation with 
gender (OR=1.03, 95% CI=0.76-1.39, P = 0.857 
and I2=0 fixed-effect), T category (OR=0.66, 
95% CI=0.22-2.03, P=0.472 and I2=81 ran-
dom-effect) or TNM stage (OR=0.64, 95% 
CI=0.39-1.04, P=0.073 and I2=60.7 random-
effect). However, NSCLC with CXCR4 expres-
sion was associated with AC (OR=1.45, 95% 
CI=1.07-1.95, P=0.016 and I2=0 fixed-effect), 
N category (OR=0.69, 95% CI=0.50-0.96, 
P=0.027 and I2=39.5 fixed-effect) and distant 
metastasis (OR=0.36, 95% CI=0.14-0.93, 
Figure 1. Flow chart of the eligible studies in the meta-analysis.
last decade. A total of 1,334 
patients with NSCLC from China, 
Italy, Japan, France, Canada, 
Korea and USA were enrolled. 
These studies were then divided 
into nuclear subgroup, in which 
CXCR4 expression was only in 
nucleus [17, 20, 22, 25], and non-
nuclear subgroup (studies detect-
ed in cytoplasm and/or membrane 
[21-24, 26], cytoplasm and nucle-
us [19] and non-nucleus [18]) in 
our present meta-analysis. In 
addition, the expression of CXCR4 
was identified by immunohisto-
chemistry (IHC) in 7 studies [19-
24, 26], by quantitative fluores-
cent IHC in 1 study [18] and by 
reverse transcription-polymerase 
chain reaction (RT-PCR) analysis 
in 2 studies [17, 25]. TNM stage 
was reported in six studies, among 
which 64.8% were stage I or II, 
while the other 35.2% were stage 
III or IV. The definition of overex-
pressed CXCR4 staining varied 
CXCR4 and cancer prognosis
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Figure 2. Forest plots of CXCR4 expression and the clinicopathological features of the patients with NSCLC. A. Gender. B. NSCLC subtype. C. Tumor depth. D. Status 
of lymph node. E. Distant metastasis. F. TNM staging.
CXCR4 and cancer prognosis
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Figure 3. Forest plots of HRs for Overall Survival (A) and Disease-free Survival (B) among the included studies.
CXCR4 and cancer prognosis
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P=0.035 and I2=67.4 random-effect) (Table 
S1).
It is worth mentioning that in the staining pat-
tern subgroup analysis, non-nuclear CXCR4 
expression had a significant association with 
TNM stage (OR=0.55, 95% CI=0.32-0.94, 
P=0.029 and I2=58.5 random-effect), AC 
(OR=1.44, 95% CI=1.03-2.00, P=0.031 and 
I2=0 fixed-effect), N category (OR=0.59, 95% 
CI=0.41-0.86, P=0.005 and I2=9.2 fixed-effect) 
and distant metastasis (OR=0.22, 95% 
CI=0.07-0.75, P=0.015 and I2=71.1 random-
effect). However, CXCR4 expression in nucleus 
had no significant association with tumor char-
acteristics (data not shown).
Impact of CXCR4 expression on 5-year OS and 
DFS rates
Nine studies (1,180 patients) were pooled into 
the meta-analysis of OS. As shown in Figure 
Table 2. Meta-analysis of CXCR4 overexpression and prognosis in NSCLC
Categories Datasets (No. of patients HR (95% CI) I² (%) Ph P 95% PI Psub
Overall survival 9 (1180) 1.59 (1.36, 1.87) 34.4 0.142 <0.001 na
Subcellular localization 0.024
    nucleus 3 (219) 0.67 (0.31, 1.44) 0 0.960 0.302 na
    non-nucleus 6 (961) 1.65 (1.40, 1.95) 28.6 0.220 <0.001 na
Ethnicity 0.225
    Non-Asian 3 (276) 1.99 (1.34, 2.95) 0 0.773 0.001 na
    Asian 6 (904) 1.52 (1.28, 1.81) 50.5 0.072 <0.001 (0.70-2.64)
Assay 0.037
    IHC 6 (852) 1.58 (1.33, 1.89) 18.9 0.290 <0.001 na
    RT-PCR 2 (158) 0.65 (0.28, 1.47) 0 0.843 0.298 na
Sample size 0.047
    <80 4 (264) 0.78 (0.38,1.60) 0 0.712 0.497 na
    >80 5 (916) 1.65 (1.40,1.94) 41.9 0.142 <0.001 na
Analysis 0.183
    univariate 5 (445) 1.94 (1.39, 2.70) 0 0.639 <0.001 na
    multivariate 4 (735) 1.50 (1.25, 1.80) 62 0.048 <0.001 (0.31, 3.02)
    Disease-free survival 5 (789) 1.00 (0.37, 2.69)R 89 <0.001 0.993 (-1.81, 4.87)
Subcellular localization <0.001
    nucleus 3 (312) 0.44 (0.26, 0.75) 0 0.644 0.002 na
    non-nucleus 2 (477) 3.06 (2.15, 4.37) 0 0.771 <0.001 na
Ethnicity 0.148
    Non-Asian 2 (308) 1.04 (0.15, 7.39) 92.3 <0.001 0.965 (-25.35, 32.89)
    Asian 3 (481) 0.95 (0.22, 4.17) 90.6 <0.001 0.951 (-4.65, 9.04)
Assay <0.001
    IHC 3 (631) 1.56 (0.48, 5.07) 90.3 <0.001 0.460 (-3.81-9.36)
    RT-PCR 2 (158) 0.48 (0.24, 0.97) 0 0.406 0.042 na
Sample size <0.001
    <80 2 (158) 0.48 (0.24, 0.97) 0 0.406 0.042 na
    >80 3 (631) 1.56 (0.48, 5.07) 90.3 <0.001 0.460 (-3.81-9.36)
Analysis <0.001
    univariate 1 (323) 3.16 (2.10-4.78) na na <0.001 na
    multivariate 4 (466) 0.73 (0.25, 2.09) 83.2 <0.001 0.554 (-2.29, 4.63)
Note: All pooled HRs were derived from fixed-effects model except for cells marked with (random R). Ph, value for heterogeneity 
based on Q test; P, value for statistical significance based on Z test; 95% PI, the distribution of true effect sizes; Psub, subgroup 
difference; Assay, the detected methods; IHC, Immunohistochemistry; RT-PCR, Reverse Transcription-polymerase Chain Reac-
tion; CI, Confidence Interval; na, not applicable.
CXCR4 and cancer prognosis
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3A, overall, high CXCR4 expression was statisti-
cally associated with a poor OS rate (HR=1.59, 
95% CI=1.36-1.87, P<0.001 and I2=34.4 fixed-
effect). Elevated CXCR4 expression in non-
nucleus was significantly associated with poor 
OS (HR=1.65, 95% CI=1.40-1.95, P<0.001 and 
I2=28.6 fixed-effect). There was not significant 
association between OS and overexpression of 
CXCR4 in nucleus. Differences between the 
two subgroups (nucleus and non-nucleus) were 
statistically significant (Psub=0.024).
Four studies (635 patients) were used in the 
meta-analysis of DFS. As shown in Figure 3B, 
overall, no significant association between 
overexpression of CXCR4 and poor DFS was 
found in these studies (HR=1, 95% CI=0.37-
2.69, P=0.993 and I2=89 random-effect). 
However, high CXCR4 expression in non-nucle-
us predicts poor DFS (HR=3.06, 95% CI=2.15-
4.37, P<0.001 and I2=0 fixed-effect). Inte- 
restingly, high CXCR4 expression in nucleus 
was significantly associated with positive DFS 
(HR=0.44, 95% CI=0.26-0.75, P=0.002 and 
I2=0 fixed-effect). Differences between the 
two subgroups were statistically significant 
(Psub<0.001).
Additional results from the subgroup analyses 
can be found in Table 2. The results suggested 
that differences between the two subgroups of 
different categories (assay-detected methods 
or patients in study) were all statistically signifi-
cant no matter for OS or for DFS. However, dif-
ferences between the analysis subgroups (uni-
variate vs multivariate) were only statistically 
significant (Psub<0.001) in DFS.
Publication bias analysis and Sensitivity analy-
sis
Begg’s tests indicated that there was no evi-
dence of significant publication bias for the 
studies included in our meta-analysis (P=0.221-
1.000, respectively). However, Egger’s test 
demonstrated a publication bias among the 
studies regarding HR of DFS with a P value of 
0.058 (P<0.10). But we did not discover any 
unpublished studies after performing the “trim 
and fill” analysis. However, based on stratifica-
tion by subcellular localization, no publication 
bias of DFS was found (Table S2). It might due 
to limited number of studies on the relationship 
between non-nuclear CXCR4 expression and 
NSCLC. Moreover, in order to gauge results sta-
bility, a sensitivity analysis, in which one study 
was deleted at a time, was performed. Both of 
the corresponding pooled ORs and HRs were 
essentially unchanged, suggesting the robust-
ness of our results.
Discussion
Several meta-analysis found that high level of 
CXCR4 appears to be associated with increased 
malignancy across cancers, as witnessed by 
the correlation with adverse characteristics 
such as poor patient survival [19, 21, 27, 28]. 
An increasing number of studies suggest a pos-
sible role for the CXCL12/CXCR4 axis in the 
metastatic evolution of NSCLC, and its poten-
tial use as prognostic markers and drug targets 
[19, 29-32]. Despite many studies showing that 
the presence of CXCR4 in the cytoplasm and/or 
nucleus is associated with a poor prognosis in 
some types of cancers such as breast, esopha-
gus, stomach and colon, the predictive value of 
CXCR4 in NSCLC is controversial. In our meta-
analysis, we attempt to evaluate the value of 
CXCR4 as a prognostic marker for NSCLC and 
determine the relationship between CXCR4 and 
clinicopathological features such as gender, 
NSCLC histologic subtype, distant metastasis 
and status of lymph node. 
In recent years, Otsuka et al. initially suggested 
that a gender-dependent difference in clinical 
outcome based on CXCR4 overexpression in 
stage IV NSCLC. Interestingly, this poor out-
come is disproportionately represented in the 
female population [18]. Subsequently, the sex 
differences in CXCR4 activity were proposed, 
along with evidence potentially linking estrogen 
receptor(ER) expression and activity to CXCR4 
function [33]. Moreover, ERs and Progesterone 
receptors (PRs) are present in stage IV NSCLC 
tissue samples, and are associated with both 
CXCR4 expression and overall survival [34]. But 
our meta-analysis did not show clear relation-
ship between CXCR4 expression and gender. 
Certainly, these different results may be owing 
to few advanced stage NSCLC patients in the 
eligible studies.
Higher expression of CXCR4 was observed in 
adenocarcinoma subtype compared to non-
adenocarcinoma samples [35] and was an 
independent predictor of a better prognosis in 
patients with lung adenocarcinoma [17]. 
Amazingly, cytomembranous expression of 
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CXCR4 in adenocarcinoma of the lung is an 
independent risk factor associated with worse 
DFS, whereas nuclear staining confers a sur-
vival benefit. These findings are consistent with 
a model in which CXCR4 promotes tumor cell 
proliferation and metastasis when present in 
the cytoplasm or cell membrane, whereas 
localization of this molecule in the nucleus pre-
vents it from exerting these effects [22]. Our 
results also suggested that CXCR4 expression 
was related to distant metastasis, status of 
lymph node and Adenocarcinoma in non-nucle-
ar subgroup but not in nuclear subgroup. 
Strong CXCR4-positive nuclear staining was 
associated with a significantly better outcome 
in NSCLC [20, 22], while cytomembranous 
expression of CXCR4 in adenocarcinoma of the 
lung is an independent risk factor associated 
with worse disease-free survival [22]. Our pres-
ent study has shown that CXCR4 is very promis-
ing for prognosis prediction. For OS, the pooled 
HR of higher CXCR4 expression was 1.59 (95% 
CI=1.36-1.87, P<0.001), which could predict 
poorer survival in NSCLC. When grouped 
according to the subcellular localization of 
CXCR4 in studies, we found that patients with 
higher CXCR4 expression of non-nuclear sub-
group showed a significantly poorer survival 
than those with lower expression. High nuclear 
expression of CXCR4 was associated with bet-
ter survival in NSCLC, but no significant differ-
ence was observed for overall survival 
(P=0.302). Similarly, high CXCR4 expression of 
non-nuclear subgroup showed a significantly 
worse disease-free survival, while CXCR4-
positive nuclear staining was remarkably asso-
ciated with a significantly better outcome in 
NSCLC. Zeelenberg et al. [36] once reported 
the retention of CXCR4 in intracellular compart-
ments (endoplasmic reticulum) of T-cell hybrid-
oma reduced metastasis and increased the 
survival of mice. So the nuclear location of 
CXCR4 may inhibit the signal provided by 
CXCL12 and result in decreased cell prolifera-
tion and metastasis. But the mechanism 
remains controversial and needs further 
exploration.
However, several points should be concerned 
about the clinical application of our findings. 
First of all, an explicit definition should be made 
about the cut-off value of CXCR4 level for 
increased survival risk. Secondly, the studies in 
our analysis used tumor tissue, and tissue may 
not be easy to obtain and therefore might not 
allow one to monitor a patient’s progress. 
Circulating markers are more acceptable than 
tissue markers because they can be assayed 
before surgery and be monitored throughout 
the life. Of potential interest is the observation 
high levels of CXCR4 could also be detected in 
patient serum [24, 27]. More studies should be 
conducted in future to evaluate the prognostic 
value of CXCR4 level in serum. The lastly, the 
studies included in the meta-analysis used vari-
ous IHC protocols (choice of CXCR4 antibody, 
dilutions of antibodies and other relevant infor-
mation), and experimental IHC protocols could 
have confounded the results. For routine clini-
cal application in the future, the above-men-
tioned problems should be addressed.
There are some limitations to the present meta-
analysis. First, the number of samples and 
studies are relatively small. What’s more, some 
of the eligible studies had insufficient informa-
tion to estimate the HRs of OS or DFS and the 
data of clinical pathological features are also 
very limited. Second, marked heterogeneity 
existed in DFS studies, possibly due to the vari-
ous cellular locations. Moreover, the applied 
method for detecting CXCR4 expression, the 
cutoff values as well as the duration of follow-
up were so different that may another source of 
variance. Although differences between the 
analysis subgroups were statistically significant 
(Psub<0.001) in DFS, but the number of studies 
in univariate subgroup was limited. The data 
suggested that analysis method of HR might 
not be the induced factor. We could not per-
form subgroup analysis to explore this influence 
because few studies offered concrete data. 
Finally, the concentrations of different antibod-
ies could influence the result.
In conclusion, our meta-analysis identified that 
aberrant overexpression of CXCR4 is associat-
ed with survival, distant metastasis, status of 
lymph node and histologic subtype in NSCLC. 
Furthermore, elevated CXCR4 expression in 
cytoplasm and whole tumor cells is markedly 
related to poor outcome. However, when elevat-
ed CXCR4 expression in nucleus, it may be a 
favorable prognostic factor in NSCLC. Further 
large-scale clinical researches should be per-
formed to investigate the precise prognostic 
significance of CXCR4 in NSCLC, especially in 
different histological types and nucleus.
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Table S1. Meta-analysis of CXCR4 overexpression and clinicopathological features in NSCLC patients
Categories Studies (No. of patients OR (95% CI) I² (%) Ph Z P 95% PI
Gender (male/female) 5 (871) 1.03 (0.76, 1.39) 0 0.764 0.18 0.857 na
NSCLC subtype (AC/Non-AC) 6 (916) 1.45 (1.07, 1.95) 0 0.625 2.41 0.016 na
T category (T1+2/T3+4) 2 (362) 0.66 (0.22, 2.03)R 81 0.004 0.72 0.472 (-3.20, 5.44)
N category (N-/N+) 4 (730) 0.69 (0.50, 0.96) 39.5 0.158 2.21 0.027 na
Distant metastasis (M0/M1) 4 (663) 0.36 (0.14, 0.93)R 67.4 0.015 2.11 0.035 (-1.91, 2.98)
TNM stage (I+II/III+IV) 4 (810) 0.64 (0.39, 1.04)R 60.7 0.038 1.8 0.073 (-0.59, 2.02)
Note: All pooled ORs were derived from fixed-effects model except for cells marked with R; R denotes random-effects model; 
Ph denotes P value for heterogeneity based on Q test; P denotes P value for statistical significance based on Z test; 95% PI 
denotes the distribution of true effect sizes; OR, Odd Ratio; CI, Confidence Interval.
Table S2. Results of Egger’s test and Begg’s test and trim and fill analysis
Comparison
Egger’s test Begg’s test Trim and Fill
t Pe 95% CI Z Pb SFP n t&fHR/OR (t&f 95% CI) ΔHR/OR
Overall survival -0.04 0.966 (-1.81, 1.74) 0.73 0.466 neither 0 1.59 (1.36, 1.87) 0
Disease-free survival -3 0.058 (-13.75, 0.41) 1.22 0.221 neither 0 1.00 (0.37, 2.69) 0
Gender (male/female) -1.4 0.233 (-5.09, 1.67) 0.38 0.707 neither 0 1.03 (0.76, 1.39) 0
NSCLC subtype (AC/Non-AC) 0.91 0.406 (-1.66, 3.47) 0 1 left 1 1.38 (1.02, 1.86) -0.07
T category (T1+2/T3+4) 3.13 0.197 (-62.10, 102.65) 1.04 0.296 left 2 0.26 (0.18, 0.37) -0.40
N category (N-/N+) -0.28 0.796 (-6.98, 5.84) 0.73 0.462 neither 0 0.69 (0.50, 0.96) 0
Distant metastasis (M0/M1) 0.49 0.66 (-5.55, 7.55) 0.24 0.806 neither 0 0.36 (0.14, 0.93) 0
TNM stage (I+II/III+IV) -1.09 0.356 (-24.55, 12.03) 0.73 0.462 neither 0 0.64 (0.39, 1.04) 0
Note: SFP denotes the side of the funnel plot where samples are imputed: L= left, R= right, N= neither; n denotes the number of samples im-
puted by trim and fill analysis; t&f HR/OR (t&f 95% CI) denotes trim and fill adjusted hazard ratio/odd ratio (trim and fill adjusted 95% confidence 
interval); ΔHR/OR denotes the difference between hazard ratio/odd ratio without trim and fill adjustment and hazard ratio/odd ratio with trim 
and fill adjustment; Pe for Egger’s test; Pb for Begg’s test.
